Pulmonary regurgitation after repaired tetralogy of Fallot: surgical versus percutaneous treatment

Juan Antonio Meca Aguirrezabalaga, Jacobo Silva Guisasola, Rocío Díaz Méndez, Alain Eliott Escalera Veizaga, Daniel Hernández-Vaquero Panizo

Department of Cardiac Surgery, Heart Area, Hospital Universitario Central de Asturias, Oviedo, Spain

Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Jacobo Silva Guisasola, MD. PhD. Head Cardiac Surgery Unit, Heart Area Department, Hospital Universitario Central de Asturias, Avenida Hospital Universitario Central de Asturias s/n, Oviedo 33011, Spain. Email: jsilva8252@yahoo.es.

Abstract: Pulmonary regurgitation is the most important sequellae after correction of Tetralogy of Fallot and has a considerable impact over the right ventricle. Surgery has demonstrated low early mortality after pulmonary valve replacement and good long-term outcomes, remaining nowadays the gold standard treatment of pulmonary regurgitation in rTOF patients. Nevertheless, transcatheter pulmonary valve implantation has emerged as a new, safe and efficient alternative to surgical valve replacement. In this review article, we try to evaluate and compare both techniques to find out which is the best therapeutic option in this patients.

Keywords: Tetralogy of Fallot (TOF); pulmonary regurgitation; pulmonary valve replacement; transcatheter pulmonary valve; congenital heart disease

doi: 10.21037/atm.2020.03.81
View this article at: http://dx.doi.org/10.21037/atm.2020.03.81

Introduction

Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease (1). The anatomic composition of this disease was first described by Etienne-Louis Fallot in 1888 (2). Due to an anterocephalad displacement of the outlet septum, we can find certain anatomical features that constitute the Tetralogy of Fallot:

(I) Large anterior malaligned ventricular septal defect (VSD; it consists in a defect (almost always unrestrictive) between the conal septum and ventricular septum;

(II) Right ventricular (RV) outflow tract obstruction (RVOT). The conal septum projects into the RVOT contributing to narrowing of the infundibulum. Frequently, we find a bicuspid pulmonary valve;

(III) RV hypertrophy, because of exposition to systemic pressure;

(IV) Dextroposition of the aorta, lying more anteriorly relative to pulmonary valve;

(V) Other cardiac abnormalities may coexist as atrial septal defects, coronary anomalies, right aortic arch, multiple ventricular septal defects and others (3).

Surgical history of tetralogy of Fallot

The first step in the treatment of TOF was taken by Helen Taussig, Alfred Blalock and Vivien Thomas in 1945, creating an arterial shunt diverting arterial blood flow from the subclavian artery to the pulmonary artery (4).

Lillehei reported the first complete intracardiac repair of TOF in 1954 utilising a large RV incision and transannular patch (5).

The first successful repair using a heart-lung machine was accomplished by Kirklin and associates in 1955 (6).

The trans-atrial anatomic repair of 1963, was popularised
by Roger Mee, reporting a mere 0.5% operative mortality and a 47 month survival of 97.5% (7).

In the following years there were many surgeons who shed light on the repair of this pathology (Ross, Somerville, Barrat-Boyes, Neutze, Castaneda) and thanks to which we have reached the current results.

Currently, transatrial and transpulmonary approaches have replaced ventriculotomy in an effort to minimize RV dysfunction and scarring. Whenever possible, annular-sparing and pulmonary valve-sparing strategies have been preferentially adopted nowadays.

Patients with TOF typically undergo VSD closure and relief of the RVOTO within the first 6 months of life. The type of surgery to relieve the RVOTO will vary depending on the patient's individual anatomy: patients with a relatively normal pulmonary valve annulus may undergo RVOT muscle bundle resection and an annular sparing approach, while those with severe pulmonary annular hypoplasia and infundibular stenosis will undergo a transannular patch (TAP) and muscle bundle resection. The patch is often carried out onto the branch pulmonary arteries as well. Patients with TOF/pulmonary atresia or those with an anomalous coronary artery crossing the RVOT may require placement of an RV-to-pulmonary-artery conduit.

**Natural evolution of repaired tetralogy of Fallot**

Despite the success in the surgery and achieve both anatomical and physiological correction, there are still complications in late survivors such as pulmonary regurgitation conditioning RV dysfunction, recurrent obstruction of the RV outflow tract, arrhythmias, sudden death, and aortic dilation and regurgitation.

Over time, rTOF patients will frequently develop some degree of RVOT dysfunction and certain degree of PR. In the first years after surgery, these residual lesions are well tolerated. Years later, there is an overload of the RV and depression of myocardial function, leading to systolic ventricular deterioration and establishing myocardial fibrosis that converts RV dysfunction into irreversible.

Due to the close interrelation between the right ventricle and the left ventricle, the lack of electromechanical synchronization of the former ends up in systolic dysfunction of the latter.

A minority group of rTOF patients will have pulmonary stenosis (PS) as their main residual lesion. Other group of rTOF patients with an RV-PA conduit will suffer a progressive conduit dysfunction with stenosis as the main lesion, with or without concomitant regurgitation.

**Indication and timing for pulmonary valve replacement (PVR)**

The main indication of a new surgery is the existence of significant pulmonary regurgitation with clinical symptoms (NYHA class III or IV). In asymptomatic patients, pulmonary valve replacement is indicated by progressive right ventricle dilatation, or dysfunction, new onset or progression of arrhythmias, and development or progression of tricuspid valve regurgitation. All these indications and summarized in the guidelines of the European Society of Cardiology (8), the American College of Cardiology/American Heart Association (9) and the Canadian Cardiovascular Society (10).

PVR can be achieved with a low early mortality, but it must be done before there is irreversible RV dysfunction and a greater propensity for VT and sudden death. It is essential to identify risk factors and thus determine the optimal timing of PVR. Cesnjevar et al. (11) talk about a “point of no return”, where the function of the RV is irreversibly affected despite performing PVR, even affecting the function of the LV.

Many studies have measured preoperative RV size thresholds in rTOF(11-17).

A study using cardiac magnetic resonance in rTOF adults showed after PVR, a significant reduction in RV volumes, while the RV systolic function was not modified. However, in patients with a RV end-diastolic volume >170 mL/m² or a RV end-systolic volume >85 mL/m² before PVR, the RV volumes did not return to normal after PVR. Normalisation of RV volumes was observed after surgery when it was performed before the end-diastolic RV volume exceeded 160 mL/m² or the end-systolic RV volume was greater than 82 mL/m² (18).

In other CMR study, Frigiola et al. examined 71 rTOF before and 1 year after PVR. Their conclusion was performing surgery with an end-diastolic volume <150 mL/m² leads to normalisation of RV volumes, recovery of biventricular function, and exercise capability (19).

Other tool to assess the timing of surgery is the QRS length. It can be lengthened years after surgery, frequently associated with the increase of RV volume and mass. Gatzoulis et al. realized that a QRS longer than 180 ms may be a warning sign of ventricular arrhythmias and sudden death, while a QRS no longer than 180 ms has a negative predictive value of 100% for these events (20).
Surgical pulmonary valve replacement

Surgical PVR can be carried out with both bioprostheses and mechanical prostheses. Bioprostheses have become the best option for PVR, but deterioration of the structural valve is still inevitable over time. Despite of this structural valve deterioration, it continues to be the type of prosthesis preferred by most surgeons.

Dehaki et al. (21) reviewed long-term outcomes of mechanical prosthesis placed in the pulmonary position in patients with congenital heart disease. They evaluated 121 with a mean age at the time of surgery was 23.1–7.9 years. The median valve size was 25 mm. All of them were discharged on oral anticoagulation with target INR of 2.5–3.5. There were no deaths during the mean follow-up of 7.0–1.9 years. Mechanical valve malfunction occurred in 10 patients (1 pannus ingrowth and 9 thrombosis). There were 3 self-limiting bleeding events.

In other study, Pragt et al. (22) analyzed data on 364 patients with pulmonary mechanical prostheses. Median follow-up was 4.26 years, mean age at implantation was 27.16±12.2 years. Freedom from valvular thrombosis was 91% at 5 years and 86% at 10 years post-PVR. Freedom from reoperation was 97% at 5 years post-PVR and 91% at 10 years.

Both studies conclude that mechanical valve prosthesis are safe and have a low rate of thrombotic complications.

The limited bioprosthesis life is related to valve type and age at implantation (23,24). Average time to reoperation is around 15 years for most adult rTOF patients (25,26). The ring of the bioprosthesis could be a good landing structure for a future valve in valve percutaneous pulmonary valve implantation (PPVI). If we are thinking about a future PPVI it is important to implant the largest possible valve.

In high-volume and experienced centers, the risk of a reoperation after rTOF is low with good long-term outcomes, but the morbidity of a new open cardiac surgery is significant, and these operations become technically more complex with every new surgery because of adhesions, fibrosis and scarring.

Ferraz Cavalcanti et al. (25) published a large meta-analysis with 3,118 patients with rTOF that underwent PVR. The pooled outcomes were: 30-day mortality was 0.87%; 5-year mortality was 2.2%; 5-year re-PVR was 4.9%. The outcomes of this meta-analysis showed that after PVR both the RV and LV experience an improvement in their volumes and function; QRS length is shortened; and NYHA class improves.

Lee et al. (15) analyzed retrospectively a cohort of 170 patients who underwent PVR for chronic PR. The median age at the time of PVR was 16.7 years. Follow-up completeness was 95%, and the median follow-up duration was 5.9 years. The overall and event-free survival at 10 years was 98% and 70%, respectively. Postoperative magnetic resonance revealed a significant improvement in biventricular function and RV volumes. A value greater than 168 mL/m² for the end-diastolic volume index of RV (EDVI) and 80 mL/m² for the end-systolic volume index of RV (ESVI) were the threshold values for irreversibility of damage. A higher preoperative ESVI RV was identified as a single independent risk factor for a suboptimal outcome.

Lim et al. (27) tried to find out the optimal timing of PVR analyzing clinical results of a cohort of 58 patients who underwent PVR after rTOF. 30-day mortality was (2.5%). Major complication occurred in three patients. Follow-up was performed for 2.5±2.4 years. There was no late death. Postoperative symptomatic group showed older age at repair of TOF, older age at PVR, longer interval between repair of TOF and PVR and longer hospital stay than postoperative asymptomatic group.

These are just a few examples of studies with surgical cohorts in which the low PVR mortality is more than evident. These studies go beyond the study of the mortality and try to analyze the impact of surgery on the RV and to infer from them the optimal time to perform surgery.

All the results of surgical studies are summarized in Table 1.

PPVI

PPVI was introduced by Bonhoeffer et al. (38) in 2000 in an attempt to minimize the number of reoperations in patients with complex congenital heart disease, who needed a valvulated biological duct. Improvements in the device initially used by Bonhoeffer led to the development of the Melody PV transcatheter.

Currently available transcatheter valve technologies are approved for use in circumferential RVOTs. This is a relatively small percentage of patients (~20–25%) with RVOT dysfunction. Off-label use of these valves for nonconduit RVOTs is feasible and increasing; however, there are still patients with an RVOT that is too large to accommodate currently existing valve technology.

Currently there are two valves approved by the FDA for its use in pulmonary position: the Medtronic Melody valve and the Edwards Sapien XT valve.

The Melody valve (Medtronic, Minneapolis, MN, USA) is approved by the US Food and Drug Administration (FDA) for use in patients with a clinical indication for intervention.
Table 1 Surgical treatment after rTOF

<table>
<thead>
<tr>
<th>First author (Ref.)</th>
<th>Sample (N)</th>
<th>30-day mortality</th>
<th>5-yr mortality</th>
<th>5-yr redo-PVR</th>
<th>Age at TOF repair mean/median (SD or range)</th>
<th>Age at PVR mean/median (SD or range)</th>
<th>Time interval TOF repair to PVR mean/median (SD or range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee et al. (15)</td>
<td>170</td>
<td>1.2</td>
<td>1.2</td>
<td>2.9</td>
<td>2 (0.2–44.1)</td>
<td>16.7 (4.6–60.2)</td>
<td>13.8 (4.0–27.5)</td>
</tr>
<tr>
<td>Jang et al. (28)</td>
<td>131</td>
<td>0</td>
<td>0</td>
<td>3.5</td>
<td>NA</td>
<td>14.8 (6.7)</td>
<td>12.5 (5.2)</td>
</tr>
<tr>
<td>Frigiola et al. (19)</td>
<td>73</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
<td>3.9 (5.2)</td>
<td>23.6 (11.5)</td>
<td>NA</td>
</tr>
<tr>
<td>Batlivala et al. (29)</td>
<td>254</td>
<td>1.2</td>
<td>1.9</td>
<td>3</td>
<td>NA</td>
<td>15.6 (3.3)</td>
<td>NA</td>
</tr>
<tr>
<td>Jain et al. (30)</td>
<td>153</td>
<td>4.6</td>
<td>3.3</td>
<td>NA</td>
<td>NA</td>
<td>33 [18–74]</td>
<td>NA</td>
</tr>
<tr>
<td>Chen et al. (31)</td>
<td>227</td>
<td>0</td>
<td>3</td>
<td>6</td>
<td>0.8 (0.01–37)</td>
<td>19.4 (0.4–58.1)</td>
<td>17.5 (0.37–46.13)</td>
</tr>
<tr>
<td>Chen et al. (32)</td>
<td>161</td>
<td>1.2</td>
<td>1.2</td>
<td>6</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Cesjnjevar et al. (11)</td>
<td>47</td>
<td>2.1</td>
<td>2.1</td>
<td>6.4</td>
<td>5.7 (9.2)</td>
<td>19.2 (12.2)</td>
<td>13.2 (7.4)</td>
</tr>
<tr>
<td>Lim et al. (27)</td>
<td>58</td>
<td>2.5</td>
<td>2.5</td>
<td>12.1</td>
<td>5.2 (7.1)</td>
<td>13.5 (9.6)</td>
<td>8.3 (5.2)</td>
</tr>
<tr>
<td>Therrien et al. (33)</td>
<td>70</td>
<td>4</td>
<td>8</td>
<td>NA</td>
<td>7 [1–40]</td>
<td>27.8 (11.9)</td>
<td>16.8 (NA)</td>
</tr>
<tr>
<td>Oosterhof et al. (13)</td>
<td>71</td>
<td>0</td>
<td>1.4</td>
<td>4.2</td>
<td>5 (2.7–4.7) IQR</td>
<td>29 [23–37]</td>
<td>NA</td>
</tr>
<tr>
<td>Zubairi et al. (35)</td>
<td>169</td>
<td>0.6</td>
<td>NA</td>
<td>7</td>
<td>NA</td>
<td>14.6 (0.6–49)</td>
<td>12 (0.6–32.1)</td>
</tr>
<tr>
<td>Scherptong et al. (36)</td>
<td>90</td>
<td>0</td>
<td>2.2</td>
<td>NA</td>
<td>5.8 (5.5)</td>
<td>31.4 (10.3)</td>
<td>NA</td>
</tr>
<tr>
<td>Gensakul et al. (37)</td>
<td>82</td>
<td>0</td>
<td>2.4</td>
<td>NA</td>
<td>9 (6.8)</td>
<td>27.9 (13.1)</td>
<td>18.9 [10]</td>
</tr>
</tbody>
</table>

TOF, tetralogy of Fallot; PVR, pulmonary valve regurgitation; NA, not available; IQR, interquartile range.

and a dysfunctional RVOT conduit or bioprosthetic valve with ≥ moderate PR and/or a mean RVOT gradient >35 mm Hg. Is a transcatheter pulmonary valve (TPV) consisting of a bovine jugular vein sutured inside of a platinum iridium stent. There are currently two available valve sizes: the TPV 20 and the TPV 22. The TPV 20 uses a 16-mm bovine jugular vein and is intended for implantation at no more than 20-mm diameter, whereas the TPV 22 is an 18-mm bovine jugular vein intended for implantation at sizes up to 22-mm diameter. The unexpanded valve height is 30 mm for the TPV 20 and 28 mm for the TPV 22. Both valves are deployed using the Medtronic Ensemble delivery system, a 22F delivery system using balloonin- balloon technology. FDA approval for implantation in failed bioprosthetic valves was received in 2017.

The SAPIEN XT (Edwards Lifesciences, Irvine, CA, USA) was approved by the FDA in March 2016 for use in dysfunctional RVOT conduits using the same criteria as noted for the Melody valve. The SAPIEN XT consists of a trileaflet bovine pericardial valve inside a cobalt chromium frame and was initially created to use it in the aortic position, as was the Edwards Lifesciences Novaflex delivery system. In comparison to the Melody valve, the SAPIEN XT is shorter. A careful evaluation before the procedure is necessary for a successful PPVI and requires the help of imaging specialists. Echocardiography is used to evaluate the systolic and diastolic function of both ventricles, as well as their measurements. The CMR image is indicated for the assessment of RV volume, RVOT morphology and suitability for PPVI.

Because of variability in coronary anatomy among this patients, approximately 5% of PPVI candidates are at risk for coronary compression after valve deployment and RVOT expansion (39). To avoid this complication, is necessary to perform a coronary angiography with simultaneous balloon inflation in the valvular landing zone. PPVI is contraindicated if coronary flow is impaired during this action.

Complications in PPVI

Stent fracture

It is the first cause of either percutaneous or surgical re-intervention due to hemodynamic compromise from RVOT.
obstruction (40,41). This occurs because of dynamic recoil of the RVOT at the cardiac cycle, overstressing the stent struts, leading to stent fracture (42).

Stent fracture is classified as type I (no loss of stent integrity), type II (loss of stent integrity), and type III (separation or embolization of the fractured segment) (43). Most of stent fractures are type I and can be managed without surgery (44).

Cabalka et al. analyzed data from the prospective North American and European Melody valve trials and reported stent fractures occurring in 81 of 251 (32%) implanted patients after a median follow up of 5 years. This study demonstrated that prestenting decreased the risk of stent fracture and that this risk was further reduced by the placement of multiple prestents. 53% of patients received multiple prestents and only 7% experienced a subsequent stent fracture, with 2 of these requiring reintervention (45).

Conduit rupture

Is a relatively common adverse event associated with rehabilitation of obstructed conduits and occurs in 19.5% to 22% of patients undergoing angioplasty (46,47). RVOT dissection or conduit rupture usually occurs due to wire perforation or balloon inflation, which can result in a morbidity and mortality increase. Fortunately, the majority of these ruptures are not clinically significant and do not lead to hemodynamic instability.

A multicenter study classified conduit rupture by severity as grade 0 (absent), grade 1 (minimal rupture), grade 2 (moderate but contained), grade 3 (severe with hemodynamic instability requiring blood transfusion) (48).

Rupture occurs more often in heavily calcified conduits. Most of the ruptures can be managed with placement of a covered stent, without open surgery (49). However, in severe cases with hemodynamic compromise, surgery may be required (50).

The Pulmonary Artery Repair With Covered Stent trial was a prospective multicenter trial assessing the safety and efficacy of using the Covered CP Stent (CCPS; NuMED, Inc) to treat conduit injury in patients undergoing intended Melody valve implantation. Conduit tears occurred in 19.5% of patients overall, with potentially life-threatening conduit tears in 1% of patients overall. Risk factors for conduit tears included smaller mean conduit diameter at implant, smaller angiographic conduit diameter before intervention, larger ratio of balloon diameter at time of injury to minimum angiographic diameter prior to any intervention, smaller minimum angiographic diameter/implant diameter, and higher baseline peak RVOT gradient. The CCPS was effective in treating 95% of conduit tears. Of the six patients with severe conduit tears, four were successfully treated with the CCPS (46).

Coronary compression

It is a potential complication preventing PPVI in approximately 5% of patients (39). It should always be assessed during the procedure. This is accomplished by simultaneously performing balloon angioplasty on the conduit (at the intended size of PPVI) while also assessing the coronary arteries with either ascending aortography or selective coronary angiography.

Endocarditis

PPV-specific endocarditis is defined by a vegetation visualized on the implant or evidence of new PPV dysfunction in the setting of a blood-stream infection. The rate of a first episode of endocarditis is 2.4% per patient-year, with a rate of 0.88% per patient-year for TPV-related endocarditis (51). Other recent meta-analysis shows a pooled incidence of endocarditis, as low as 0.6 per 100 person-years for PPV-specific endocarditis and 1.4 per 100 person-years overall (52). This patients can be safely managed with antibiotics. Worse cases may require surgical explantation of the valve (51). Continued screening and having in mind the risk for endocarditis are necessary during follow-up of any patient receiving a PPVI.

Clinical outcomes of PPVI

The 2010 guidelines from the European Society of Cardiology and Association for European Pediatric Cardiology recommend PPVI with the same indications as surgical PV replacement (8).

Boshoff et al. (53) reported 23 off-label cases of PPVI. The peak RVOT gradient was significantly decreased, and no more than mild PR was observed in a mean follow-up of 1.2 years. A second procedure because of restenosis were required in 2 patients. There were no vascular complications, SF, or valve migration during follow-up.

Cheatham et al. reported outcomes of the US Investigational Device Exemption trial out to 7 years after PPVI in 150 patients who received a Melody valve implant (54). The authors showed that primary valve failure is rare, and TPV dysfunction is primarily manifested by
Table 2  Percutaneous treatment after rTOF

<table>
<thead>
<tr>
<th>First author (ref)</th>
<th>Sample (N)</th>
<th>Age at PPVI (years)</th>
<th>Weight (kg)</th>
<th>Follow-up (months)</th>
<th>Valve</th>
<th>Success (none or mild PR)</th>
<th>Redo</th>
<th>PR*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lurz et al. (56)</td>
<td>155</td>
<td>21.2</td>
<td>NA</td>
<td>25.4</td>
<td>Melody</td>
<td>NA</td>
<td>23 QX; 22 TC</td>
<td>4</td>
</tr>
<tr>
<td>McElhinney et al. (57)</td>
<td>136</td>
<td>19</td>
<td>NA</td>
<td>NA</td>
<td>Melody</td>
<td>99.1%</td>
<td>1 QX; 10 TC</td>
<td>2</td>
</tr>
<tr>
<td>Kenny et al. (55)</td>
<td>36</td>
<td>30.3</td>
<td>73.4</td>
<td>6</td>
<td>SAPIEN</td>
<td>95.5%</td>
<td>3 QX; 1 TC</td>
<td>1</td>
</tr>
<tr>
<td>Armstrong et al. (58)</td>
<td>101</td>
<td>19.9</td>
<td>59.4</td>
<td>12</td>
<td>Melody</td>
<td>98%</td>
<td>2 QX; 0 TC</td>
<td>0</td>
</tr>
<tr>
<td>Butera et al. (40)</td>
<td>63</td>
<td>24</td>
<td>60</td>
<td>30</td>
<td>Melody</td>
<td>93.6%</td>
<td>3 QX; 2 TC</td>
<td>1</td>
</tr>
<tr>
<td>Kenny et al. (55)</td>
<td>36</td>
<td>30.3</td>
<td>73.4</td>
<td>6</td>
<td>SAPIEN</td>
<td>95.5%</td>
<td>3 QX; 1 TC</td>
<td>1</td>
</tr>
<tr>
<td>Armstrong et al. (58)</td>
<td>101</td>
<td>19.9</td>
<td>59.4</td>
<td>12</td>
<td>Melody</td>
<td>98%</td>
<td>2 QX; 0 TC</td>
<td>0</td>
</tr>
<tr>
<td>Butera et al. (40)</td>
<td>63</td>
<td>24</td>
<td>60</td>
<td>30</td>
<td>Melody</td>
<td>93.6%</td>
<td>3 QX; 2 TC</td>
<td>1</td>
</tr>
<tr>
<td>Cheatham et al. (54)</td>
<td>150</td>
<td>19</td>
<td>NA</td>
<td>54</td>
<td>Melody</td>
<td>NA</td>
<td>8 QX; 28 TC</td>
<td>1</td>
</tr>
<tr>
<td>Khammadkone et al. (59)</td>
<td>59</td>
<td>16</td>
<td>56</td>
<td>9.8</td>
<td>Melody</td>
<td>98.3%</td>
<td>8 QX; 5 TC</td>
<td>1</td>
</tr>
<tr>
<td>Eicken et al. (60)</td>
<td>102</td>
<td>21.5</td>
<td>63</td>
<td>11.7</td>
<td>Melody</td>
<td>NA</td>
<td>2 QX; 9 TC</td>
<td>NA</td>
</tr>
<tr>
<td>Haas et al. (61)</td>
<td>22</td>
<td>21.7</td>
<td>56.5</td>
<td>5.7</td>
<td>SAPIEN</td>
<td>95.5%</td>
<td>0 QX; 1 TC</td>
<td>NA</td>
</tr>
</tbody>
</table>

*, moderate or severe pulmonary regurgitation at latest follow-up. PPVI, percutaneous pulmonary valve implantation; PR, pulmonary regurgitation; QX, surgical; TC, transcatheter.

Both surgery and PPVI have shown excellent outcomes, but even today, there is no study that compares them directly. Surgery continues to be the gold standard for PVR after rTOF, with a large number of studies that support its good outcomes and long follow-ups. Even so, PPVI is proving to be a safe therapy with good outcomes comparable to those of surgery, although studies with longer follow-ups are still necessary.

### Conclusions

Both surgery and PPVI are good alternatives in PVR after rTOF due to its excellent results. PPVI appears on the scene as a safe and effective alternative to open surgery. There is still a need for greater follow-up in the cohorts of patients undergoing PPVI to be able to match the existing surgical studies to assess the durability of the prosthesis and its results. Studies that directly compare percutaneous treatment versus open surgery are also necessary.

It is necessary to see these two types of techniques as complementary tools in the treatment of our patients and not as competing techniques, perhaps thinking that in the not too distant future, the hybrid technique will become the gold standard in the treatment of this pathology.
Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editor (Daniel Hernández-Vaquero) for the series “Structural Heart Disease: The Revolution” published in *Annals of Translational Medicine*. The article was sent for external peer review organized by the Guest Editor and the editorial office.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.03.81). The series “Structural Heart Disease: The Revolution” was commissioned by the editorial office without any funding or sponsorship. DHVP served as the unpaid Guest Editor of the series and serves as an unpaid editorial board member of *Annals of Translational Medicine* from Aug 2019 to Jul 2021. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


60. Eicken A, Ewert P, Hager A, et al. Percutaneous...
pulmonary valve implantation: two-centre experience with more than 100 patients. Eur Heart J 2011;32:1260-5.